Carfilzomib con­tinues to show promising results in multiple myeloma according to four studies presented in a poster session yesterday at the 2010 American Society of Hematology annual meeting in Orlando.

Carfilzomib (Kyprolis), developed by Onyx Pharmaceuticals, is a new drug that is cur­rently being in­ves­ti­gated as a potential treat­ment for multiple myeloma. It belongs to the same class of drugs as Velcade (bor­tez­o­mib). However it works slightly differently by binding to different proteins than Velcade.

Recent research has indicated that car­filz­o­mib is effective for patients with re­lapsed or refractory (resistant) myeloma who …

The American Society of He­ma­tol­ogy meeting swung into full gear yesterday. The day was full of invited talks and a poster session.

The morn­ing kicked off with an education session in which attendees could learn about sev­er­al myeloma-related topics.

The first pre­sen­ta­tion was by Dr. Ola Landgren from the National Cancer In­sti­tute and National In­sti­tutes of Health in Bethesda, Maryland. Dr. Landgren spoke about mono­clonal gam­mop­athy of undetermined sig­nif­i­cance (MGUS) and smol­der­ing myeloma, precursor dis­eases of mul­ti­ple myeloma.

A study pub­lished by Dr. Landgren last year showed that all mul­ti­ple myeloma patients have …

The 52nd annual meeting of the American Society of Hematology (ASH) will kick off this Saturday, December 4, in Orlando. Experts from around the world will present the latest research about various blood diseases, including multiple myeloma, and The Myeloma Beacon will provide comprehensive coverage of the meeting as it happens.

“The Myeloma Beacon will be a one-stop source for myeloma-related news from the ASH meeting,” said Boris Simkovich, publisher of The Myeloma Beacon.

Similar to the Beacon’s coverage of the American Society of Clinical Oncology meeting in June, The Beacon will …

The 52nd annual meeting of the American Society of Hematology will take place Saturday, December 4, through Tuesday, December 7.

During the four-day meeting, clinical specialists from all over the world will discuss current research regarding the diagnosis and treatment of various blood diseases, including multiple myeloma. Over 20,000 people are expected to attend the event.

The American Society of Hematology (ASH) meeting will include many presentations and posters focused on myeloma. The ASH website currently lists about 350 myeloma-related abstracts that will be presented in various poster sessions and oral presentations …